Tarsus Pharmaceuticals Inc

TARS remains in a Stage 4 decline with price well below major EMAs. A recent relief rally toward the 9/21 EMA zone has been capped, offering a tactical sell opportunity. No clear exhaustion or reversal signal has emerged despite extreme oversold readings. Medium-term structure stays bearish, and execution favors selling into rallies at dynamic resistance. A sustained close above the EMAs would invalidate this bearish stance.

• ↑Q1 2026 Xtemvi net sales $145.4 M (+85% YoY) driven by DTC campaign and physician uptake.
• ↑Full-year 2026 Xtemvi sales guidance $670–700 M implies continued robust demand.
• ↓Culper short report alleges illegal Medicare copay assistance, raising regulatory scrutiny.